- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03345082
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
January 8, 2021 updated by: Opthea Limited
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
A multicentre, randomised, parallel group, sham-controlled, double-masked, dose-ranging study, investigating two doses of OPT-302 in combination with ranibizumab compared with ranibizumab with sham, over six consecutive monthly dosing cycles in participants with neovascular (wet) AMD.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
366
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hradec Králové, Czechia, 50005
- Opthea Investigational Site
-
Praha, Czechia, 12808
- Opthea Investigational Site
-
Praha 10, Czechia, 10034
- Opthea Investigational Site
-
-
-
-
-
Créteil, France, 94010
- Opthea Investigational Site
-
Dijon, France, 21079
- Opthea Investigational Site
-
Paris, France, 75010
- Opthea Investigational Site
-
Paris, France, 75019
- Opthea Investigational Site
-
Strasbourg, France, 67090
- Opthea Investigational Site
-
Écully, France, 69130
- Opthea Investigational Site
-
-
-
-
-
Budapest, Hungary, 1062
- Opthea Investigational Site
-
Budapest, Hungary, 1133
- Opthea Investigational Site
-
Budapest, Hungary
- Opthea Investigational Site
-
Nyíregyháza, Hungary
- Opthea Investigational Site
-
Szeged, Hungary, 6720
- Opthea Investigational Site
-
-
-
-
-
Haifa, Israel, 31048
- Opthea Investigational Site
-
Haifa, Israel
- Opthea Investigational Site
-
Jerusalem, Israel, 91031
- Opthea Investigational Site
-
Jerusalem, Israel
- Opthea Investigational Site
-
Kfar Saba, Israel
- Opthea Investigational Site
-
Petach Tikva, Israel
- Opthea Investigational Site
-
Reẖovot, Israel
- Opthea Investigational Site
-
Tel Aviv, Israel
- Opthea Investigational Site
-
-
-
-
-
Bologna, Italy, 40138
- Opthea Investigational Site
-
Florence, Italy, 50134
- Opthea Investigational Site
-
Milan, Italy, 20157
- Opthea Investigational Site
-
Milan, Italy
- Opthea Investigational Site
-
Roma, Italy, 00133
- Opthea Investigational Site
-
-
-
-
-
Jelgava, Latvia
- Opthea Investigational Site
-
Riga, Latvia, 1006
- Opthea Investigational Site
-
Riga, Latvia, 1009
- Opthea Investigational Site
-
Riga, Latvia
- Opthea Investigational Site
-
-
-
-
-
Bydgoszcz, Poland
- Opthea Investigational Site
-
Gdańsk, Poland
- Opthea Investigational Site
-
Katowice, Poland
- Opthea Investigational Site
-
Kraków, Poland
- Opthea Investigational Site
-
Lublin, Poland, 20079
- Opthea Investigationa Site
-
Lublin, Poland
- Opthea Investigational Site
-
Wrocław, Poland
- Opthea Investigational Site
-
-
-
-
-
Barcelona, Spain
- Opthea Investigational Site
-
Bilbao, Spain
- Opthea Investigational Site
-
Madrid, Spain
- Opthea Investigational Site
-
Oviedo, Spain
- Opthea Investigational Site
-
Pamplona, Spain
- Opthea Investigational Site
-
Santiago De Compostela, Spain
- Opthea Investigational Site
-
Valencia, Spain
- Opthea Investigational Site
-
Valladolid, Spain
- Opthea Investigational Site
-
-
-
-
-
Bristol, United Kingdom
- Opthea Investigational Site
-
Frimley, United Kingdom
- Opthea Investigational Site
-
Glasgow, United Kingdom
- Opthea Investigational Site
-
London, United Kingdom
- Opthea Investigational Site
-
Maidstone, United Kingdom
- Opthea Investigational Site
-
Sheffield, United Kingdom
- Opthea Investigational Site
-
Wolverhampton, United Kingdom
- Opthea Investigational Site
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85014
- Opthea Investigational Site
-
Phoenix, Arizona, United States, 85020
- Opthea Investigational Site
-
-
California
-
Beverly Hills, California, United States, 90211
- Opthea Investigational Site
-
Encino, California, United States, 91436
- Opthea Investigational Site
-
Palm Desert, California, United States, 92260
- Opthea Investigational Site
-
Redlands, California, United States, 92374
- Opthea Investigational Site
-
Sacramento, California, United States, 95819
- Opthea Study Site
-
Sacramento, California, United States, 95841
- Opthea Investigational Site
-
San Diego, California, United States, 94143
- Opthea Investigational Site
-
Santa Ana, California, United States, 92705
- Opthea Investigational Site
-
Santa Barbara, California, United States, 93103
- Opthea Investigational Site
-
Santa Maria, California, United States, 93454
- Opthea Investigational Site
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80909
- Opthea Investigational Site
-
Golden, Colorado, United States, 80401
- Opthea Investigational Site
-
-
Florida
-
Boynton Beach, Florida, United States, 33426
- Opthea Investigational Site
-
Fort Myers, Florida, United States, 33907
- Opthea Investigational Site
-
Fort Myers, Florida, United States, 33912
- Opthea Investigational Site
-
Melbourne, Florida, United States, 32901
- Opthea Investigational Site
-
Pensacola, Florida, United States, 32503
- Opthea Investigational Site
-
Saint Petersburg, Florida, United States, 33703
- Opthea Investigational Site
-
Tallahassee, Florida, United States, 32308
- Opthea Investigational Site
-
Winter Haven, Florida, United States, 33880
- Opthea Investigational Site
-
-
Georgia
-
Augusta, Georgia, United States, 30909
- Opthea Investigational Site
-
-
Kansas
-
Shawnee Mission, Kansas, United States, 66204
- Opthea Investigational Site
-
Wichita, Kansas, United States, 67214
- Opthea Investigational Site
-
-
Kentucky
-
Paducah, Kentucky, United States, 42001
- Opthea Investigational Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21204
- Opthea Investigational Site
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49546
- Opthea Investigational Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89144
- Opthea Investigational Site
-
Reno, Nevada, United States, 89502
- Opthea Investigational Site
-
-
New Jersey
-
Edison, New Jersey, United States, 08820
- Opthea Investigational Site
-
Teaneck, New Jersey, United States, 07666
- Opthea Investigational Site
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87109
- Opthea Investigational Site
-
-
New York
-
Lynbrook, New York, United States, 11563
- Opthea Investigational Site
-
Rochester, New York, United States, 14620
- Opthea Investigational Site
-
Syracuse, New York, United States, 13224
- Opthea Investigational Site
-
-
North Carolina
-
Asheville, North Carolina, United States, 28803
- Opthea Investigational Site
-
Charlotte, North Carolina, United States, 28210
- Opthea Investigational Site
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Opthea Investigational Site
-
Columbus, Ohio, United States, 43212
- Opthea Investigational Site
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Opthea Investigational Site
-
-
Pennsylvania
-
Camp Hill, Pennsylvania, United States, 17011
- Opthea Investigational Site
-
Kingston, Pennsylvania, United States, 18704
- Opthea Investigational Site
-
Philadelphia, Pennsylvania, United States, 19107
- Opthea Investigational Site
-
-
South Carolina
-
Ladson, South Carolina, United States, 29456
- Opthea Investigational Site
-
West Columbia, South Carolina, United States, 29169
- Opthea Investigational Site
-
-
Texas
-
Abilene, Texas, United States, 79606
- Opthea Investigational Site
-
Austin, Texas, United States, 78705
- Opthea Investigational Site
-
Houston, Texas, United States, 77030
- Opthea Investigational Site
-
San Antonio, Texas, United States, 78240
- Opthea Investigational Site
-
The Woodlands, Texas, United States, 77384
- Opthea Investigational Site
-
Willow Park, Texas, United States, 76087
- Opthea Investigational Site
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Opthea Investigational Site
-
Virginia Beach, Virginia, United States, 23462
- Opthea Investigational Site
-
-
Washington
-
Silverdale, Washington, United States, 98383
- Opthea Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Active subfoveal choroidal neovascular (CNV) lesion or juxtafoveal lesion secondary to age-related macular AMD
- An ETDRS BCVA score between 60 and 25 (inclusive) letters
Exclusion Criteria:
- Previous treatment for wet AMD or previous treatment for CNV due to other causes in the Study Eye
- Clinically significant ocular disorders which may interfere with assessment of visual acuity, assessment of toxicity, or fundus photography in the Study Eye
- Poorly controlled diabetes mellitus (defined as HbA1c>7%)
- Any clinically significant cardiovascular, renal or hepatic conditions, recent surgery, or malignancy, that would make the participant unsuitable for the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 0.5 mg ranibizumab with 2.0 mg OPT-302
0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by 2.0 mg OPT-302 intravitreal injection (0.05 ml)
|
Intravitreal injection
Intravitreal injection
Other Names:
|
Experimental: 0.5 mg ranibizumab with 0.5 mg OPT-302
0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by 0.5 mg OPT-302 intravitreal injection (0.05 ml)
|
Intravitreal injection
Intravitreal injection
Other Names:
|
Sham Comparator: 0.5 mg ranibizumab with sham
0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by sham
|
Intravitreal injection
Other Names:
Sham (mock) intravitreal injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) best corrected visual acuity (BCVA)
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of participants gaining 15 or more ETDRS BCVA letters
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
Area under the ETDRS BCVA over time curve
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
Change in central subfield thickness (CST) on spectral domain optical coherence tomography (SD-OCT)
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
Change in intra-retinal fluid and sub-retinal fluid on SD-OCT
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
Proportion of participants losing 15 or more letters (on ETDRS BCVA chart)
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Study Director, Opthea Limited
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 6, 2017
Primary Completion (Actual)
May 14, 2019
Study Completion (Actual)
May 14, 2019
Study Registration Dates
First Submitted
November 14, 2017
First Submitted That Met QC Criteria
November 14, 2017
First Posted (Actual)
November 17, 2017
Study Record Updates
Last Update Posted (Actual)
January 12, 2021
Last Update Submitted That Met QC Criteria
January 8, 2021
Last Verified
January 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OPT-302-1002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neovascular Age-related Macular Degeneration
-
Novartis PharmaceuticalsActive, not recruitingNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hoffmann-La RocheNot yet recruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheRecruitingNeovascular Age-Related Macular DegenerationBelgium, United States, Italy, Argentina, Spain, United Kingdom, Israel, Australia, Austria, Brazil, Germany, Switzerland, Taiwan, France
-
Hoffmann-La RocheCompletedNeovascular Age-Related Macular DegenerationUnited States
-
Novartis PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
Clinical Trials on OPT-302
-
Opthea LimitedCompletedEye Diseases | Macular Degeneration | Retinal Degeneration | Retinal Diseases | Neovascularization, PathologicUnited States
-
Shenzhen Xbiome Biotech Co., Ltd.Beijing Improve-Quality Tech.Co., Ltd.Recruiting
-
Opthea LimitedCompletedDiabetic Macular EdemaUnited States, Israel, Australia, Latvia
-
Mackay Memorial HospitalOBI Pharma, IncUnknown
-
Opthea LimitedActive, not recruitingNeovascular Age-related Macular DegenerationUnited States, Argentina, Australia, Austria, Brazil, Bulgaria, Canada, Colombia, Croatia, Czechia, Denmark, Estonia, France, Germany, Greece, Hungary, India, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, Philippines and more
-
Johns Hopkins Bloomberg School of Public HealthMakerere University; Pontificia Universidad Javeriana; The Bloomberg Family Foundation...CompletedUse of Consent Language and Mode to Improve Interactive Voice Response Survey in Colombia and UgandaNoncommunicable Diseases | Surveys and QuestionnairesColombia, Uganda
-
First Affiliated Hospital of Harbin Medical UniversityCompleted
-
NYU Langone HealthNational Institute on Drug Abuse (NIDA)CompletedSmoking CessationUnited States
-
University of PennsylvaniaCompletedCancer of the Colon
-
Threshold PharmaceuticalsCompletedAcute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | High-risk Myelodysplastic Syndrome | Advanced MyelofibrosisUnited States